ALG-020572 is an antisense oligonucleotide designed to degrade hepatitis B viral mRNA and reduce viral protein synthesis — addressing the acknowledged failure of current therapy to suppress HBsAg.
Part 1 gave single ascending doses up to 480 mg to 32 healthy participants. It was well tolerated, the commonest adverse event was injection site reaction, and pharmacokinetics were clean.
Part 2 enrolled eight participants with non-cirrhotic, HBeAg-negative, virologically suppressed chronic hepatitis B for up to seven doses. Four of the eight developed significant ALT elevations attributed to drug-induced liver injury. The study was terminated, and development of the compound stopped.
The sequence is the lesson. A drug entirely safe in healthy volunteers injured half the patients it was intended for, at doses the healthy cohort tolerated. The authors attribute it to idiosyncratic injury and explicitly caution about the class. For a chronic hepatitis B population, where the therapeutic goal is functional cure in patients who are already virologically suppressed and largely asymptomatic, the tolerable risk is very low — these patients are not unwell, and a drug that injures the organ it is meant to protect has no path forward.
- Healthy-volunteer safety did not predict safety in the target population
- Four of eight treated patients — a signal that needed no statistics
- Development discontinued; the authors caution about the whole class
- Patients were virologically suppressed and non-cirrhotic — a low-risk-tolerance group
- The unmet need remains: current therapy does not suppress HBsAg
The statistics, in plain English
Four events in eight patients needs no significance test — when the event rate is this high and the outcome this serious, the observation is the finding. The instructive part is the contrast with Part 1: 32 healthy participants tolerated the drug, which demonstrates that phase 1 safety in healthy volunteers can be uninformative about safety in the diseased organ a drug targets.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free